JP7461104B2 - Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 - Google Patents

Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 Download PDF

Info

Publication number
JP7461104B2
JP7461104B2 JP2018223465A JP2018223465A JP7461104B2 JP 7461104 B2 JP7461104 B2 JP 7461104B2 JP 2018223465 A JP2018223465 A JP 2018223465A JP 2018223465 A JP2018223465 A JP 2018223465A JP 7461104 B2 JP7461104 B2 JP 7461104B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
minutes
independently selected
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018223465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019099571A5 (https=
JP2019099571A (ja
Inventor
仁 吉野
智史 土屋
篤 松尾
勉 佐藤
昌弘 西本
京子 小栗
紘子 小川
祥和 西村
佳之 古田
浩孝 柏木
伸行 堀
拓麻 家門
拓也 白石
昌伸 吉田
隆博 河合
智嗣 谷田
雅英 青木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JP2019099571A publication Critical patent/JP2019099571A/ja
Publication of JP2019099571A5 publication Critical patent/JP2019099571A5/ja
Priority to JP2024045935A priority Critical patent/JP7767492B2/ja
Application granted granted Critical
Publication of JP7461104B2 publication Critical patent/JP7461104B2/ja
Priority to JP2025182210A priority patent/JP2026016628A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018223465A 2017-11-29 2018-11-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 Active JP7461104B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024045935A JP7767492B2 (ja) 2017-11-29 2024-03-22 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A JP2026016628A (ja) 2017-11-29 2025-10-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017228661 2017-11-29
JP2017228661 2017-11-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024045935A Division JP7767492B2 (ja) 2017-11-29 2024-03-22 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Publications (3)

Publication Number Publication Date
JP2019099571A JP2019099571A (ja) 2019-06-24
JP2019099571A5 JP2019099571A5 (https=) 2022-01-06
JP7461104B2 true JP7461104B2 (ja) 2024-04-03

Family

ID=66975925

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018223465A Active JP7461104B2 (ja) 2017-11-29 2018-11-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2024045935A Active JP7767492B2 (ja) 2017-11-29 2024-03-22 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A Pending JP2026016628A (ja) 2017-11-29 2025-10-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024045935A Active JP7767492B2 (ja) 2017-11-29 2024-03-22 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A Pending JP2026016628A (ja) 2017-11-29 2025-10-29 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Country Status (1)

Country Link
JP (3) JP7461104B2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110618208A (zh) * 2019-09-10 2019-12-27 威海迪素制药有限公司 一种（s）-（+）-3-羟基四氢呋喃对映异构体含量检测方法
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
US12037339B2 (en) * 2020-07-20 2024-07-16 Eccogene Inc. Substituted imidazoles as GLP-1 receptor agonists
EP4211133A4 (en) * 2020-09-07 2024-11-27 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CN116368140A (zh) * 2020-09-10 2023-06-30 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023016546A1 (en) * 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
EP4522131A1 (en) * 2022-05-11 2025-03-19 Eli Lilly and Company Glp1 tablet compositions
PE20260136A1 (es) * 2022-05-11 2026-01-21 Lilly Co Eli Composiciones farmaceuticas de glp1
CN120712085A (zh) * 2022-12-13 2025-09-26 伊莱利利公司 Orforglipron用于治疗患有2型糖尿病(t2d)、肥胖症或超重伴至少一种体重相关合并症的个体的剂量方案
IL321043A (en) * 2022-12-15 2025-07-01 Sironax Ltd SARM1 modulators, their preparations and uses
CN120659776A (zh) * 2022-12-19 2025-09-16 伊莱利利公司 Glp1 ra及其中间体的制备方法
EP4652167A1 (en) * 2023-01-17 2025-11-26 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2025002250A1 (zh) * 2023-06-29 2025-01-02 韦恩生物科技有限公司 一种glp-1受体激动剂及其制备方法和用途
IL325536A (en) * 2023-06-30 2026-02-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A compound containing a multi-fused ring structure
TW202508571A (zh) * 2023-07-28 2025-03-01 大陸商上海翰森生物醫藥科技有限公司 一種苯并含氮雜環類衍生物調節劑、其製備方法和應用
WO2025026436A1 (zh) * 2023-08-02 2025-02-06 韦恩生物科技有限公司 一种含氮并环化合物及其制备方法和用途
CN121941685A (zh) 2023-11-10 2026-04-28 重庆药友制药有限责任公司 一种glp-1r激动剂化合物及其应用
TW202542146A (zh) * 2023-12-05 2025-11-01 大陸商信達生物科技有限公司 靶向ｇｌｐ－１受體的化合物以及其用途
WO2025124357A1 (zh) * 2023-12-14 2025-06-19 广东众生睿创生物科技有限公司 一种杂环glp-1受体激动剂及其应用
WO2025209515A1 (zh) * 2024-04-03 2025-10-09 广州市联瑞制药有限公司 一种glp-1受体激动剂及其制备方法和应用
WO2025261454A1 (zh) * 2024-06-19 2025-12-26 上海翰森生物医药科技有限公司 一种含氮大环化合物衍生物调节剂及其制备方法和应用
WO2026001866A1 (zh) * 2024-06-24 2026-01-02 联邦生物科技(珠海横琴)有限公司 一种glp-1受体激动剂及其应用
WO2026012449A1 (zh) * 2024-07-12 2026-01-15 联邦生物科技(珠海横琴)有限公司 一种具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026032183A1 (en) * 2024-08-05 2026-02-12 Rongchang Pharmaceuticals, Ltd. Nitrogen-containing fused ring compound, pharmaceutical composition and use thereof
WO2026052129A1 (zh) * 2024-09-09 2026-03-12 中国科学院上海药物研究所 多环杂芳烃类glp-1受体激动剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510582A (ja) 2002-08-26 2006-03-30 武田薬品工業株式会社 カルシウム受容体調節化合物およびその用途
JP2010510987A (ja) 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
JP2012522060A (ja) 2009-03-30 2012-09-20 トランス テック ファーマ，インコーポレイテッド 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
WO2016038045A1 (en) 2014-09-08 2016-03-17 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Pyrazolopyridine derivatives and their use in therapy
JP2016508506A (ja) 2013-02-06 2016-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
JP6567778B2 (ja) 2016-09-26 2019-08-28 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510582A (ja) 2002-08-26 2006-03-30 武田薬品工業株式会社 カルシウム受容体調節化合物およびその用途
JP2010510987A (ja) 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
JP2012522060A (ja) 2009-03-30 2012-09-20 トランス テック ファーマ，インコーポレイテッド 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
JP2016508506A (ja) 2013-02-06 2016-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
WO2016038045A1 (en) 2014-09-08 2016-03-17 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Pyrazolopyridine derivatives and their use in therapy
JP6567778B2 (ja) 2016-09-26 2019-08-28 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Also Published As

Publication number Publication date
JP2026016628A (ja) 2026-02-03
JP2024079762A (ja) 2024-06-11
JP2019099571A (ja) 2019-06-24
JP7767492B2 (ja) 2025-11-11

Similar Documents

Publication Publication Date Title
JP7602573B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体
JP7767492B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
HK40004131B (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
NZ751725B2 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
EA044109B1 (ru) Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
HK40004131A (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190516

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240322

R150 Certificate of patent or registration of utility model

Ref document number: 7461104

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150